Pediatrix Medical Group/$MD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Pediatrix Medical Group
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
- Ticker
- $MD
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 4,280
- Headquarters
- Sunrise, United States
- Website
- www.pediatrix.com
MD Metrics
BasicAdvanced
$2.3B
16.33
$1.83
0.61
-
Price and volume
Market cap
$2.3B
Beta
0.61
52-week high
$30.55
52-week low
$16.90
Average daily volume
695K
Financial strength
Current ratio
1.277
Quick ratio
1.918
Long term debt to equity
0.496
Total debt to equity
0.72
Interest coverage (TTM)
7.15%
Profitability
EBITDA (TTM)
261.752
Gross margin (TTM)
26.12%
Net profit margin (TTM)
7.66%
Operating margin (TTM)
12.15%
Effective tax rate (TTM)
26.22%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
6.86%
Return on equity (TTM)
17.25%
Valuation
Price to earnings (TTM)
16.325
Price to revenue (TTM)
1.206
Price to book
2.67
Price to tangible book (TTM)
-3.97
Price to free cash flow (TTM)
11.268
Free cash flow yield (TTM)
8.87%
Free cash flow per share (TTM)
2.646
Growth
Revenue change (TTM)
1.91%
Earnings per share change (TTM)
-4.32%
3-year revenue growth (CAGR)
-0.88%
10-year revenue growth (CAGR)
-4.47%
3-year earnings per share growth (CAGR)
17.29%
10-year earnings per share growth (CAGR)
-6.67%
What the Analysts think about MD
Analyst ratings (Buy, Hold, Sell) for Pediatrix Medical Group stock.
Analyst projections of the future price of Pediatrix Medical Group stock.
Bulls say / Bears say
Pediatrix lifted its 2026 adjusted EBITDA outlook to $290–300 million from the previous $280–300 million range. Third-quarter adjusted EPS was $0.72, up from $0.67 a year earlier. (Business Wire)
Revenue rose 3.2% in the first nine months of 2026, with same-unit revenue up 2.0%; recent acquisitions also added activity. In the third quarter, same-unit revenue increased 0.6%, with modest growth from both reimbursement and patient volume. (Business Wire)
Pediatrix ended September with $311.9 million in cash and no borrowings on its $450 million revolving credit line, giving it funding flexibility. It also repurchased $83 million of shares in the quarter, reducing the share count. (Business Wire)
Third-quarter net income fell to $47 million from $71.7 million a year earlier, while adjusted EBITDA slipped to $85 million from $87.3 million, despite revenue growth. This points to pressure on underlying profitability. (Business Wire)
Patient volumes remain a constraint: in the second quarter, same-unit patient-service volume fell 2.1%, including a 3.2% drop in NICU days. Management expected full-year volumes to be flat or slightly lower, limiting growth if pricing tailwinds fade. (Business Wire, Yahoo Finance)
Reimbursement is exposed to policy changes: CMS proposed a 1.19% cut to the Medicare physician fee schedule conversion factor for 2027, and revised rules for out-of-network payment disputes could limit what Pediatrix recovers. A shift towards government-funded payors could also hurt, as they pay less than commercial insurers for equivalent services. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
MD Financial Performance
Revenues and expenses
MD Earnings Performance
Company profitability
Upcoming events
No upcoming events
MD News
AllArticlesVideos
Funds containing MD
Fund name | Fund size | $MD weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.21% |
iShares Ageing Population£AGES | $953M | 0.21% |
iShares Ageing Population€AGED | $903M | 0.21% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.13% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.